samedan logo
 
 
spacer
home > white papers > Planning the Execution of a Viral Clearance Study - Eurofins BioPharma Product Testing
WHITE PAPERS
logo_Eurofins.jpg

Eurofins BioPharma Product Testing

phone +32 2 766 16 20
email pharma@eurofins.com
web http://www.eurofins.com/Biopharma
email Chaussée de Malines, 455 B-1950 Kraainem

Planning the Execution of a Viral Clearance Study

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Global Industry Research Leader MarketsandMarkets Raises $56 Million in Growth Equity Led by FTV Capital


More info >>


White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>


Industry Events

Orphan Drugs and Rare Diseases Europe 2017

15-16 May 2017,

SMi is proud to announce the return of their 6th annual Orphan Drugs event to Berlin on the 15th -16th May 2017! The global orphan drug market totaled nearly $123 billion in 2014 and will continue to grow to reach nearly $191 billion by 2019.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement